Develops therapies to treat heart diseases associated with inflammation and fibrosis.
Symbol: | CRDL |
---|---|
Quote: | 1.20 |
Change: | -0.10 |
Change %: | -7.69% |
High: | 1.32 |
Low: | 1.19 |
Open: | 1.30 |
---|---|
Volume: | 217,107 |
52 Week: | 1.15-3.12 |
P/E Ratio: | -3.16 |
EPS: | -0.38 |
Market Cap: | 97.92 M |
Cardiol Therapeutics Inc. is a clinical-stage life sciences company based in Oakville, Canada, dedicated to advancing therapies for cardiovascular disease (CVD) through innovative anti-fibrotic and anti-inflammatory treatments. At the forefront of its research is CardiolRx, the company's leading product currently undergoing Phase II/III multi-national trials. These studies are pivotal in assessing CardiolRx's efficacy and safety as a cardioprotective therapy aimed at reducing cardiovascular and respiratory events in hospitalized COVID-19 patients, as well as its potential in treating acute myocarditis.
In addition to its ongoing clinical trials, Cardiol Therapeutics is actively developing a subcutaneous formulation of CardiolRx. This formulation is specifically tailored to target fibrosis and inflammation in the heart, conditions intricately linked to the progression and development of heart failure. By focusing on these critical areas of cardiovascular health, the company aims to adress significant unmet medical needs and improve patient outcomes.
Founded in 2017, Cardiol Therapeutics has quickly positioned itself as a leader in the field of cardiovascular therapeutics. The company's headquarters in Oakville serve as a hub for its research and development efforts, bolstered by a commitment to rigorous scientific inquiry and strategic partnerships aimed at advancing novel treatments that hold promise for patients worldwide.
Exchange: | NASDAQ |
---|---|
Beta: | 0.665 |
Industry: | Drug Manufacturers - Specialty & Generic |
Sector: | Healthcare |
Employees: | 22 |
IPO Date: | Jan 15, 2019 |
![]() Data demonstrates improvement in cardiac function and reductions in cardiac hypertrophy, remodeling, inflammation, and cell death - key underlying mechanisms in heart failure Toronto, Ontario--(Newsfile Corp. - February 20, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences comp... 4 days ago |
![]() Toronto, Ontario--(Newsfile Corp. - February 4, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, is pleased to announce that it will pr... 20 days ago |
![]() Innovation is at its peak for the Zacks Medical-Drugs industry. CORT, AMRX, DYN, NKTR and CRDL may prove to be good additions to one's portfolio. 24 days ago |
![]() Cardiol Therapeutics President and CEO, David Elsley NEW YORK, Dec. 19, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView announces the release of an informative interview with Cardiol Therapeutics President and CEO, David Elsley, who discusses the company's lead oral drug, CardiolRx™, which is entering a late-stage Phase III clinical trial, MAVERIC, for p... 2 months ago |
![]() Known for their uncommonly pronounced risk/reward profile, penny stocks all too often entice investors with their low prices and potential for significant returns, only to fail to live up to those expectations. The world of penny stocks is also characterized by pump-and-dump and other scams, facilitated by the fact that most penny stock companies d... 2 months ago |